Chinese Journal of Stroke ›› 2022, Vol. 17 ›› Issue (10): 1120-1126.DOI: 10.3969/j.issn.1673-5765.2022.10.014
Previous Articles Next Articles
Received:
2022-04-24
Online:
2022-10-20
Published:
2022-10-20
韩广淞,倪俊
通讯作者:
倪俊 pumchnijun@163.com
HAN Guangsong, NI Jun. Advances in Clinical Classification of Moyamoya Disease [J]. Chinese Journal of Stroke, 2022, 17(10): 1120-1126.
韩广淞, 倪俊. 烟雾病临床分型研究进展[J]. 中国卒中杂志, 2022, 17(10): 1120-1126.
[1] KIM J S. Moyamoya disease:epidemiology,clinical features,and diagnosis[J]. J Stroke,2016,18(1):2-11. [2] SHANG S L,ZHOU D,YA J Y,et al. Progress in moyamoya disease[J]. Neurosurg Rev,2020,43(2):371-382. [3] TAKEUCHI K,SHIMIZU K. Hypoplasia of the bilateral internal carotid arteries[J]. Brain Nerve,1957,9(1):37-43. [4] SATO Y,KAZUMATA K,NAKATANI E,et al. Characteristics of moyamoya disease based on national registry data in Japan[J]. Stroke,2019,50(8):1973-1980. [5] AHN I M,PARK D H,HANN H J,et al. Incidence,prevalence,and survival of moyamoya disease in Korea:a nationwide,population-based study[J]. Stroke,2014,45(4):1090-1095. [6] BAO X Y,WANG Q N,ZHANG Y,et al. Epidemiology of moyamoya disease in China:single-center,population-based study[J/OL]. World Neurosurg,2019,122:e917-e923[2022-04-20]. https://doi.org/10.1016/j.wneu.2018.10.175. [7] ZHANG D,HUANG L G,HUANG Z,et al. Epidemiology of moyamoya disease in China:a nationwide hospital-based study[J/OL]. Lancet Reg Health West Pac,2021,18:100331[2022-04-20]. https://doi.org/10.1016/j.lanwpc.2021.100331. [8] SUZUKI J,KODAMA N. Moyamoya disease-a review[J]. Stroke,1983,14(1):104-109. [9] KURODA S,HOUKIN K. Moyamoya disease:current concepts and future perspectives[J]. Lancet Neurol,2008,7(11):1056-1066,2008. [10] BABA T,HOUKIN K,KURODA S. Novel epidemiological features of moyamoya disease[J]. J Neurol Neurosurg Psychiatry,2008,79(8):900-904. [11] 高山,倪俊,黄家星,等. 烟雾病临床特点分析[J]. 中华神经科杂志,2006,39(3):176-179. [12] YAMADA M,FUJII K,FUKUI M. Clinical features and outcomes in patients with asymptomatic moyamoya disease-from the results of nation-wide questionnaire survey[J]. No Shinkei Geka,2005,33(4):337-342. [13] MIAO W,ZHAO P L,ZHANG Y S,et al. Epidemiological and clinical features of moyamoya disease in Nanjing,China[J]. Clin Neurol Neurosurg,2010,112(3):199-203. [14] DUAN L,BAO X Y,YANG W Z,et al. Moyamoya disease in China:its clinical features and outcomes[J]. Stroke,2012,43(1):56-60. [15] SCOTT R M,SMITH E R. Moyamoya disease and moyamoya syndrome[J]. N Engl J Med,2009,360(12):1226-1237. [16] WANG Y,YANG L P,WANG X T,et al. Meta-analysis of genotype and phenotype studies to confirm the predictive role of the RNF213 p. R4810K variant for moyamoya disease[J]. Eur J Neurol,2021,28(3):823-836. [17] WU Z Y,JIANG H Q,ZHANG L,et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population[J/OL]. PLoS One,2012,7(10):e48179[2022-04-20]. https://doi.org/10.1371/journal.pone.0048179. [18] CECCHI A C,GUO D C,REN Z,et al. RNF213 rare variants in an ethnically diverse population with moyamoya disease[J]. Stroke,2014,45(11):3200-3207. [19] BANG O Y,CHUNG J W,CHA J,et al. A polymorphism in RNF213 is a susceptibility gene for intracranial atherosclerosis[J/OL]. PLoS One,2016,11(6):e0156607[2022-04-20]. https://doi.org/10.1371/journal.pone.0156607. [20] RAFAT N,BECK G C H,PEÑA-TAPIA P G,et al. Increased levels of circulating endothelial progenitor cells in patients with moyamoya disease[J]. Stroke,2009,40(2):432-438. [21] GUO D C,PAPKE C L,TRAN FADULU V,et al. Mutations in smooth muscle alpha-actin(ACTA2)cause coronary artery disease,stroke,and moyamoya disease,along with thoracic aortic disease[J]. Am J Hum Genet,2009,84(5):617-627. [22] WANG X,HAN C,JIA Y J,et al. Proteomic profiling of exosomes from hemorrhagic moyamoya disease and dysfunction of mitochondria in endothelial cells[J]. Stroke,2021,52(10):3351-3361. [23] LU J L,WANG J Y,LIN Z D,et al. MMP-9 as a biomarker for predicting hemorrhagic strokes in moyamoya disease[J/OL]. Front Neurol,2021,12:721118[2022-04-20]. https://doi.org/10.3389/fneur.2021.721118. [24] LU M M,ZHANG H T,LIU D Q,et al. Association of intracranial vessel wall enhancement and cerebral hemorrhage in moyamoya disease:a high-resolution magnetic resonance imaging study[J]. J Neurol,2021,268(12):4768-4777. [25] KATHUVEETIL A,SYLAJA P N,SENTHILVE-LAN S,et al. Vessel wall thickening and enhancement in high-resolution intracranial vessel wall imaging:a predictor of future ischemic events in moyamoya disease[J]. AJNR Am J Neuroradiol,2020,41(1):100-105. [26] ZHAO M,ZHANG D,WANG S,et al. Posterior circulation involvement in pediatric and adult patients with moyamoya disease:a single center experience in 574 patients[J]. Acta Neurol Belg,2018,118(2):227-233. [27] TAN C X,DUAN R,YE X,et al. Posterior circulation moyamoya disease versus primitive vertebral-basilar artery system moyamoya disease:new classification of moyamoya disease from the perspective of embryology[J/OL]. World Neurosurg,2016,96:222-229[2022-04-20]. https://doi.org/10.1016/j.wneu.2016.08.099. [28] JANG D K,LEE K S,RHA H K,et al. Clinical and angiographic features and stroke types in adult moyamoya disease[J]. AJNR Am J Neuroradiol,2014,35(6):1124-1131. [29] FUNAKI T,TAKAHASHI J C,YOSHIDA K,et al. Periventricular anastomosis in moyamoya disease:detecting fragile collateral vessels with MR angiography[J]. J Neurosurg,2016,124(6):1766-1772. [30] HIRANO Y,MIYAWAKI S,IMAI H,et al. Differences in clinical features among different onset patterns in moyamoya disease[J]. J Clin Med,2021,10(13):2815. [31] KURODA S,AMORE Study Group. Asymptomatic moyamoya disease:literature review and ongoing AMORE study[J]. Neurol Med Chir(Tokyo),2015,55(3):194-198. [32] HERVÉ D,KOSSOROTOFF M,BRESSON D,et al. French clinical practice guidelines for moyamoya angiopathy[J]. Rev Neurol(Paris),2018,174(5):292-303. [33] 烟雾病治疗中国专家共识编写组. 烟雾病治疗中国专家共识[J]. 国际脑血管病杂志,2019,27(9):645-650. [34] LU J L,SHI G C,ZHAO Y L,et al. Effects and safety of aspirin use in patients after cerebrovascular bypass procedures[J]. Stroke Vasc Neurol,2021,6(4):624-630. [35] KURODA S,HASHIMOTO N,YOSHIMOTO T,et al. Radiological findings,clinical course,and outcome in asymptomatic moyamoya disease:results of multicenter survey in Japan[J]. Stroke,2007,38(5):1430-1435. |
[1] | GUI Jinmin, XUE Rui, LI Na, LIU Qinglin, ZHAO Donghong. Individualized Management of Blood Pressure and Liquid Control for Moyamoya Patients with Hyperperfusion Syndrome after Extracranial-Intracranial Bypass [J]. Chinese Journal of Stroke, 2022, 17(12): 1350-1354. |
[2] | SONG Yanli, LIN Jie, WU Yiping, LI Xiaojing, LIU Gaifen, XIA Wenjing, ZHANG Yuying, ZHANG Xiaolin, LYU Chenran, ZHOU Hong, LI Kai, XUE Bin, CHEN Lingling, ZHANG Zhongbo, PENG Xiao. Epidemiological Survey on the Risk Factors of Cardio-Cerebrovascular Diseases among Residents in Handan and Influencing Factors of Awareness, Treatment and Control Rate of Hypertension [J]. Chinese Journal of Stroke, 2022, 17(12): 1360-1365. |
[3] | WANG Yubo, LI Zixiao, WANG Yongjun. Progress of the Relationship between Epigenetics and Oxidative Stress after Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(11): 1171-1177. |
[4] | CHENG Anqi, XU Weihai. Advances in Genetics of Stroke in Young Adults [J]. Chinese Journal of Stroke, 2022, 17(09): 920-924. |
[5] | FU Heguan, SHEN Xuxuan, XU Jiali, ZHANG Houdi, LI Bin, ZOU Zhengxing, FENG Jie, DUAN Lian, HAN Cong. The Types and Risk Factors of Stroke in Young Patients with Moyamoya Disease [J]. Chinese Journal of Stroke, 2022, 17(09): 937-943. |
[6] | XU Luyao, CHEN Xiaodi, LIANG Zhigang. Advances in Imaging Evaluation of Post-stroke Aphasia [J]. Chinese Journal of Stroke, 2022, 17(09): 1017-1021. |
[7] | LIU Chengchun, TANG Chunhua, HUANG Shuhan, WU Ya, LI Xiaoshu, LI Wei, ZHANG Meng. Emergent Management of Anterior Circulation Tandem Occlusion with Large Core Infarction [J]. Chinese Journal of Stroke, 2022, 17(08): 834-839. |
[8] | LIU Ziyue, ZHU Yicheng. Progress of Reperfusion Therapy for In-hospital Stroke [J]. Chinese Journal of Stroke, 2022, 17(07): 695-705. |
[9] | KANG Shuai, HAN Heze, LU Junlin, CHEN Xiaolin, CHEN Yu, YE Xun, WANG Rong, ZHAO Yuanli. Incidence and Risk Factors of Non-infective Fever after Cerebral Revascularization in Moyamoya Disease [J]. Chinese Journal of Stroke, 2022, 17(07): 742-747. |
[10] | CUI Xiaoyu, NIE Ximing, LIU Liping. Correlation of Hypoprealbuminemia and Outcome after Endovascular Treatment for Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(07): 758-763. |
[11] | LIU Yonghui, YANG Kan, QIN Fubin, CHEN Wenwen, HE Tingting, HUANG Yadi. Progress of Headache due to Reversible Cerebral Vasoconstriction Syndrome [J]. Chinese Journal of Stroke, 2022, 17(05): 455-460. |
[12] | LU Jiajie, ZHAO Hongru. Headache Phenotypes and Possible Mechanisms of Dural Arteriovenous Fistula [J]. Chinese Journal of Stroke, 2022, 17(05): 461-465. |
[13] | BAO Xiangyang, DUAN Lian. Cultivation and Teaching Experience of Postgraduates in Moyamoya Disease [J]. Chinese Journal of Stroke, 2022, 17(04): 426-428. |
[14] | XU Zhe, CHENG Si, LIU Yang, SHI Yanfeng, LI Hao. Construction of Bioinformatics Pipeline for Genomics Data in Cerebral Vascular Disease Researches [J]. Chinese Journal of Stroke, 2022, 17(03): 217-226. |
[15] | LIU Yang, XU Zhe, CHENG Si, SHI Yanfeng, LIN Jinxi, MENG Xia, JIANG Yong, LI Hao. Clinical Research-Oriented Gene Sequencing Projects: Rationale, Management and Quality Control Standards [J]. Chinese Journal of Stroke, 2022, 17(03): 227-235. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||